Non-inferiority trials have become an essential instrument in clinical research, particularly when the goal is to demonstrate that an experimental treatment is not unacceptably worse than an ...
The BOOG 2013-08 trial evaluates whether SLNB can be safely omitted for patients with clinically T1-2N0 treated with ...
TipRanks on MSN
MicroPort NeuroTech steps up competition in brain vascular devices with new embolic agent trial
MicroPort NeuroTech Limited ($HK:2172) announced an update on their ongoing clinical study. Study Overview The clinical study “a Prospective, ...
EyePoint Pharmaceuticals receives a reiterated sell rating due to ongoing clinical and commercial uncertainties despite recent progress in DME and wet AMD trials. Duravyu (EYP-1901) showed positive ...
Paris, France, 14-17 May 2024. The Course Directors have selected 3 major Late Breaking Trials (LBTs) that will be presented for the first time during the 2024 edition of EuroPCR. These trials were ...
Please provide your email address to receive an email when new articles are posted on . Tapering regimens were linked to significantly higher flare risk among patients in RA remission. The results ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Please provide your email address to receive an email when new articles are posted on . KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Ashkan M. Abbey, MD, discusses 1-year results ...
A new £50 million initiative aims to cut the length of time novel medicines spend in clinical trials, enabling patients to benefit from new treatments much sooner.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback